CFOTO | Future Publishing | Getty Images
The Food and Drug Administration on Monday approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization among babies in the U.S.
Pfizer’s RSV shot is already approved and available in the U.S. for older adults.
It’s now the second treatment approved by the FDA to prevent RSV in infants and the first vaccine. It uses maternal immunization, which refers to vaccinating pregnant mothers so they can pass protective antibodies to their fetuses.
Pending a recommendation by the Centers for Disease Control and Prevention, Pfizer hopes the vaccine will be available to the public by the end of October or the beginning of November, which marks the beginning of RSV season, according to Alejandra Gurtman, the company’s senior vice president of clinical research and development for vaccines.
“When you think globally, this vaccine could potentially have a huge public health impact,” Gurtman told…
2023-08-21 16:59:03
Source from www.cnbc.com